Recent Updates
Recently added Catalysts

REC-994

Phase 2

Cerebral Cavernous Malformation | Small Molecules | Neurology |Recursion Pharmaceuticals, Inc.|Trials Updated: Oct 22, 2026

REC-994 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Oct 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment62

FDA Designations

ORPHAN_DRUG

REC-994 clinical trials

REC-994 · 1 trial · 1 indication

Phase 2 1
NCT05085561The Symptomatic Cerebral Cavernous Malformation Trial of REC-994Cerebral Cavernous Malformation
COMPLETED62 Analytics
PHASE2COMPLETED
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
Cerebral Cavernous MalformationUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Up to a maximum of 1201 days

A TEAE was the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. TEAES which include treatment related TEAEs, serious TEAEs, treatment-related serious TEAEs, TEAEs leading to treatment discontinuation, and treatment-related TEAEs leading to treatment discontinuation are reported. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section

Secondary Endpoints

Part 1: Change From Baseline in Modified Rankin Scale (mRS) Score at Month 12
Baseline, Month 12
Part 1: Change From Baseline in Total SymptoMScreen (SMSS) Score at Month 12
Baseline, Month 12
Part 1: Change From Baseline in Cerebral Cavernous Malformation Health Index (CCM-HI) Total Score at Month 12
Baseline, Month 12
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
REC-994 200 mgEXPERIMENTALParticipants received REC-994 200 milligrams (mg) orally once daily (QD) (1 200 mg REC-994 tablet, 1 matching placebo tablet)
REC-994 400 mgEXPERIMENTALParticipants received REC-994 400 mg orally QD (2 200 mg REC-994 tablets)
PlaceboPLACEBO_COMPARATORParticipants received matching placebo orally QD (2 matching placebo tablets)

Interventions

NameTypeDescription
REC-994DRUGREC-994 200 mg tablets
PlaceboDRUGPlacebo Tablets
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites15

Inclusion criteria: 1. 18 years of age or older with anatomic CCM lesions demonstrated by brain MRI 2. Have symptomatic CCM 3. Have provided written informed consent to participate in the study 4. Have not participated in a clinical trial utilizing an investigational agent within 28 days or within ...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about REC-994

What is REC-994 used for?

REC-994 is an investigational small molecule being developed for the treatment of Cerebral Cavernous Malformation (CCM), a neurological condition characterized by abnormal clusters of blood vessels in the brain and spinal cord. It is currently in Phase 2 clinical development.

Who makes REC-994?

REC-994 is being developed by Recursion Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RXRX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Cerebral Cavernous Malformation.

What phase is REC-994 in?

REC-994 is in Phase 2 clinical development. It has completed a Phase 2 trial, and it is not yet approved by the FDA. The drug has received Orphan Drug designation from the FDA for the treatment of Cerebral Cavernous Malformation.

What clinical trials is REC-994 in?

REC-994 has one completed Phase 2 clinical trial with the identifier NCT05085561, titled 'The Symptomatic Cerebral Cavernous Malformation Trial of REC-994.' This randomized, double-blind, placebo-controlled study enrolled 62 participants in the United States.

Is REC-994 FDA approved?

REC-994 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Cerebral Cavernous Malformation. The FDA has granted it Orphan Drug designation, which provides incentives to support its development, but it has not yet received marketing approval.